ARTICLE | Clinical News
Undisclosed intranasal compound: Phase II started
November 24, 2008 8:00 AM UTC
Serenity began a Phase II trial. The compound was developed using the CPE-215 drug delivery technology from CPEX, which spun out from Bentley Pharmaceuticals Inc. (AMEX:BNT, Exeter, N.H.) earlier thi...